GenixPharmaceucticals Corporation (GENX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GenixPharmaceucticals Corporation (GENX) has a cash flow conversion efficiency ratio of 0.021x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-30.25K ≈ $-21.88K USD) by net assets (CA$-1.47 Million ≈ $-1.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GenixPharmaceucticals Corporation - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how GenixPharmaceucticals Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of GenixPharmaceucticals Corporation for a breakdown of total debt and financial obligations.
GenixPharmaceucticals Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GenixPharmaceucticals Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Troubadour Resources Inc
V:TR
|
-0.017x |
|
DP Poland Plc
LSE:DPP
|
0.097x |
|
NeutriSci International Inc
V:NU
|
0.006x |
|
Nuwellis Inc
NASDAQ:NUWE
|
-0.804x |
|
OSX Brasil S.A
SA:OSXB3
|
-0.001x |
|
STRATA Skin Sciences Inc
NASDAQ:SSKN
|
-0.082x |
|
Nicolas Miguet et Associes SA
PA:MLNMA
|
N/A |
|
Asian Television Network International Ltd
V:SAT
|
-0.121x |
Annual Cash Flow Conversion Efficiency for GenixPharmaceucticals Corporation (2015–2025)
The table below shows the annual cash flow conversion efficiency of GenixPharmaceucticals Corporation from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see GENX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | CA$-1.42 Million ≈ $-1.03 Million |
CA$-124.07K ≈ $-89.75K |
0.087x | -44.79% |
| 2024-10-31 | CA$-1.18 Million ≈ $-855.91K |
CA$-187.34K ≈ $-135.52K |
0.158x | -18.39% |
| 2023-10-31 | CA$-1.14 Million ≈ $-822.75K |
CA$-220.67K ≈ $-159.63K |
0.194x | +382.67% |
| 2022-10-31 | CA$3.20 Million ≈ $2.31 Million |
CA$-219.58K ≈ $-158.84K |
-0.069x | +35.67% |
| 2021-10-31 | CA$4.01 Million ≈ $2.90 Million |
CA$-428.31K ≈ $-309.83K |
-0.107x | -165.74% |
| 2020-10-31 | CA$4.86 Million ≈ $3.51 Million |
CA$-195.03K ≈ $-141.08K |
-0.040x | -102.89% |
| 2019-10-31 | CA$-42.13K ≈ $-30.48K |
CA$-58.55K ≈ $-42.35K |
1.390x | +398.33% |
| 2018-10-31 | CA$122.57K ≈ $88.66K |
CA$34.18K ≈ $24.72K |
0.279x | +460.73% |
| 2017-10-31 | CA$120.97K ≈ $87.51K |
CA$-9.35K ≈ $-6.76K |
-0.077x | +82.00% |
| 2016-10-31 | CA$384.43K ≈ $278.09K |
CA$-165.07K ≈ $-119.41K |
-0.429x | +51.91% |
| 2015-10-31 | CA$506.89K ≈ $366.67K |
CA$-452.55K ≈ $-327.37K |
-0.893x | -- |
About GenixPharmaceucticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral,… Read more